Shares of Valeant Pharmaceuticals International Inc (NYSE:VRX) were gapping up Wednesday morning with an open price 10.3% higher than Tuesday's closing price. The stock closed at $44.39 Tuesday and opened today's trading at $48.94.
The average volume for Valeant Pharmaceuticals International has been 2.5 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $13.5 billion and is part of the health care sector and drugs industry. Shares are up 56.9% year to date as of the close of trading on Tuesday. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets various pharmaceutical products primarily in the areas of neurology, dermatology, and branded generics. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Valeant Pharmaceuticals International Ratings Report.
The average volume for Valeant Pharmaceuticals International has been 2.5 million shares per day over the past 30 days. Valeant Pharmaceuticals International has a market cap of $13.5 billion and is part of the health care sector and drugs industry. Shares are up 56.9% year to date as of the close of trading on Tuesday. Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets various pharmaceutical products primarily in the areas of neurology, dermatology, and branded generics. TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. You can view the full Valeant Pharmaceuticals International Ratings Report.
No comments:
Post a Comment